Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.
The American Cancer Society expects 600,920 Americans to die from cancer this year, but Ziopharm Oncology Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) aim to lower that figure. Both of these clinical-stage biotechs are developing some exciting new treatment options, and success could lead to monstrous gains over the long run.
Here's a closer look at what they've got cooking in clinical trials to see which stock is a better pick at the moment.
Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Stock
€32.20
3.210%
Celldex Therapeutics is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
With a target price of 62 € there is a hugely positive potential of 92.55% for Celldex Therapeutics compared to the current price of 32.2 €.
